Current Issue : January-March Volume : 2025 Issue Number : 1 Articles : 1 Articles
Fatty liver disease (FLD), particularly non-alcoholic fatty liver disease (NAFLD), is a growing global health concern, affecting approximately 25% of the adult population. It can progress to non-alcoholic steatohepatitis (NASH), leading to severe liver complications. This study evaluates the effectiveness of targeting Diacylglycerol O-acyltransferase 2 (DGAT2) and enhancing urea cycle function as dual therapeutic strategies to reverse fatty liver progression. A prospective, multi-center clinical trial was conducted involving 100 adults aged 18-65 years diagnosed with moderate to severe NAFLD. Participants were randomized into three groups: DGAT2 inhibitor therapy, urea cycle enhancers and combination therapy. Outcome measures included changes in hepatic triglyceride levels, liver enzyme levels (ALT, AST), ammonia levels and quality of life assessed via SF-36. Significant reductions in hepatic triglycerides (30%) and liver enzyme levels were observed in the DGAT2 inhibitor group. Urea cycle enhancers led to a 43% decrease in ammonia levels, while combination therapy achieved a 45% reduction in hepatic fat. Histological improvement was noted in 75% of cases. Targeting both DGAT2 and urea cycle dysregulation presents a promising therapeutic strategy for managing fatty liver disease, offering a comprehensive approach to treatment....
Loading....